Royalty Pharma: Investor Day Upside (NASDAQ:RPRX)

Group 1 - The core viewpoint is that Royalty Pharma plc (NASDAQ: RPRX) continues to demonstrate consistent execution, leading to a recommendation of a Buy rating following their Investor Day and Q2 results [1] - The company is supported by buy-side hedge professionals who conduct fundamental, income-oriented, long-term analysis across sectors globally in developed markets [1] Group 2 - The article emphasizes that the analysis is based on the author's own opinions and does not involve compensation from any company mentioned [2] - There is a beneficial long position in the shares of RPRX, indicating confidence in the company's future performance [2]